BASE scientists leverage the facility’s unique manufacturing capabilities to drive research into new RNA and DNA technologies, and their innovative application in health, industry and agriculture.
mRNA vaccines and therapies.
Synthetic mRNA therapies provide a new strategy to treat disease. mRNA vaccines have proven effective vaccines to protect against COVID-19, and hold incredible potential to protect against infectious disease and cancer. mRNA therapies can also replace defective proteins and can treat inherited disease.
The BASE facility specialises in the production in mRNA vaccines and therapies for use in research and pre-clinical studies.
RNA 2.0 technologies
BASE scientists are building the next generation of RNA technologies. We identify RNA structures, sequences, and modifications that control mRNA translation, stability, and localisation in specific cell types and developmental stages.
These elements are originally sourced from human genes, non-coding RNAs and viral genomes and subsequently optimised using engineering principles, and screened with our high-throughput multiplexed cellular assays.
Synthetic DNA and RNA must be manufactured at scale with purity. BASE scientists are constantly developing new methods of manufacture, including enzymatic DNA synthesis, engineered enzymes and RNA processing pathways that improve bioprocessing. These advances are complemented by new tools and software that analyse RNA quality using next-generation sequencing.
The BASE facility is an international leader in establishing reference materials and standards that enable coordination between a global network of laboratories to provide distributed surge capacity to meet mRNA vaccine needs during future pandemics.
Combining biology with engineering principles allows the design and construction of biological systems. BASE scientists use rational design to build genes, genomes and organisms that provide innovative solutions in health, industry and agriculture.
BASE facility scientists have experience in designing and synthesising molecular devices, including engineered enzymes and RNA sensors. Given our capabilities in DNA synthesis, we are building new genes and organisms to produce products, optimise industrial processes and remediate waste.